TransCode Therapeutics Net Income

As of the most recent data (June 2026), RNAZ shows a net income of $-63B. That compares with $-14B in the prior-year period — down 334.4% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RNAZ's net income is now $-63B (was $-14B) — a 334.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether TransCode Therapeutics is outperforming or lagging.

The Healthcare sector average net income is about $16B. TransCode Therapeutics is at $-63B, which is lower that average. That is roughly 493.8% below the sector mean. Use the comparison chart on this page to see how RNAZ stacks up against individual peers as well.

Tracking RNAZ's net income over time shows whether TransCode Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-63B That compares with $-14B in the prior-year period — down 334.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has TransCode Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-63B) with ownership activity and broader fundamentals.